Phytochemical Name : Forskolin

Properties Information
PhytoCAT-ID PhytoCAT-2190
Phytochemical name or plant extracts Forskolin
PMID 29574069
Literature evidence Recently, forskolin is emerging as a possible novel molecule for cancer therapy.
IUPAC name [(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-5-yl] acetate
Phytochemicals’ class or type of plant extracts Labdane diterpenoid
Source of phytochemicals or plant Extracts Coleus barbatus
Geographical availability Burundi, China South-Central, East Himalaya, Eritrea, Ethiopia, India, Kenya, Nepal, Oman, Rwanda, Saudi Arabia, Somalia, Sri Lanka, Sudan, Tanzania, Thailand, Uganda, West Himalaya, Yemen, Zaïre
Plant parts NA
Other cancers Breast cancer, Cervical cancer
Target gene or protein ERK1/2
Gene or Protein evidence Forskolin improves sensitivity to doxorubicin of triple negative breast cancer cells via Protein Kinase A-mediated ERK1/2 inhibition
Target pathways NA
IC50 NA
Potency Our findings sustain the evidence of anticancer activity mediated by forskolin and encourage the design of future in-vivo/clinical studies in order to explore forskolin as a doxorubicin sensitizer for possible use in TNBC patients.
Cell line/ mice model MDA-MB-231, MDA-MB-468, MCF7, HeLa
Additional information  It is important to note that the forskolin-induced potentiation of sensitivity to doxorubicin is accompanied by a strong inhibition of ERK1/2 phosphorylation, is mimicked by ERK inhibitor PD98059 and is prevented by pre-treatment with Protein Kinase A (PKA) and adenylate cyclase inhibitors. Altogether, our data indicate that forskolin sensitizes TNBC cells to doxorubicin via a mechanism depending on the cAMP/PKA-mediated ERK inhibition.
PubChem ID 47936
Additional PMIDs 24593874
Additional sources of information https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:60454692-2
Safety NA